NCT01861041

Brief Summary

Spinal anesthesia, is used during the transuretheral resection of the prostate.Low dose hyperbaric local anesthetics have been used to enhance the resolution of the spinal block. We compared the efficacy and duration of the spinal block with two different bupivacaine baricities.

  • Group I: low dose isobaric group
  • GroupII: Low dose hyperbaric group

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
52

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started May 2013

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

May 15, 2013

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 23, 2013

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
Last Updated

May 23, 2013

Status Verified

May 1, 2013

Enrollment Period

2 months

First QC Date

May 15, 2013

Last Update Submit

May 21, 2013

Conditions

Keywords

low dosedifferent baricityspinal anesthesia

Outcome Measures

Primary Outcomes (1)

  • Spinal Block Quality

    Sensory block assesment with pinpric test.

    15 minute after intrathecal injection

Secondary Outcomes (1)

  • Spinal block regression

    5 minute after arrival at PACU

Study Arms (2)

Heavy Bupivacain, Local anesthetic, Amp

EXPERIMENTAL

Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml

Drug: Heavy Bupivacaine

Isobaric spinal, Local anesthetic, Amp

ACTIVE COMPARATOR

7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml

Drug: Isobaric Bupivacaine

Interventions

7,5 mg intrathecal hyperbaric bupivacain,

Also known as: marcaine heavy
Heavy Bupivacain, Local anesthetic, Amp

7.5 mg intratecal isobaric bupivacain

Also known as: Marcain flakon
Isobaric spinal, Local anesthetic, Amp

Eligibility Criteria

Age50 Years - 85 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years ASA 1-4 BENİGN PROSTAT HYPERPLASİ

You may not qualify if:

  • Allergy of study drugs
  • Morbid obesity
  • Spinal anesthesia contrindications
  • Bleeding dyscrasias

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Diskapi Yildirim Beyazit Education and Research Hospital

Ankara, 06610, Turkey (Türkiye)

Location

Related Publications (2)

  • Loubert C, Hallworth S, Fernando R, Columb M, Patel N, Sarang K, Sodhi V. Does the baricity of bupivacaine influence intrathecal spread in the prolonged sitting position before elective cesarean delivery? A prospective randomized controlled study. Anesth Analg. 2011 Oct;113(4):811-7. doi: 10.1213/ANE.0b013e3182288bf2. Epub 2011 Sep 2.

    PMID: 21890887BACKGROUND
  • Kim SY, Cho JE, Hong JY, Koo BN, Kim JM, Kil HK. Comparison of intrathecal fentanyl and sufentanil in low-dose dilute bupivacaine spinal anaesthesia for transurethral prostatectomy. Br J Anaesth. 2009 Nov;103(5):750-4. doi: 10.1093/bja/aep263. Epub 2009 Sep 28.

    PMID: 19797249BACKGROUND

MeSH Terms

Conditions

Prostatic Hyperplasia

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • MURAT M SAYIN, Ass. Prof

    Dispapi yildirim beyazit E R hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

May 15, 2013

First Posted

May 23, 2013

Study Start

May 1, 2013

Primary Completion

July 1, 2013

Study Completion

July 1, 2013

Last Updated

May 23, 2013

Record last verified: 2013-05

Locations